What is AbbVie's strategy for the obesity market?

AbbVie is developing an amylin-mimicking drug to compete in the growing obesity treatment market.

How does Gubra's drug differ from GLP-1 drugs?

Gubra's amylin-mimicking drug aims for more weight loss with fewer side effects compared to GLP-1 drugs.

Why is AbbVie interested in weight loss treatments?

AbbVie sees a significant opportunity in the projected $150 billion annual weight loss drug market.

Home / Business and Economy / AbbVie Bets on Amylin for Next-Gen Weight Loss Drugs

AbbVie Bets on Amylin for Next-Gen Weight Loss Drugs

15 Jan

•

Summary

AbbVie is developing an amylin-mimicking drug for obesity.
The drug could offer better weight loss with fewer side effects.
AbbVie leverages its aesthetics business for weight loss market.

AbbVie Bets on Amylin for Next-Gen Weight Loss Drugs

AbbVie is making a significant move into the booming obesity treatment sector, focusing on a novel amylin-mimicking drug obtained through a license with Gubra. This strategic expansion targets a market poised for substantial growth, aiming to address limitations of existing therapies.

The drug, which replicates the hormone amylin, is designed to provide a new alternative to popular GLP-1 drugs like Wegovy and Zepbound. AbbVie's goal is to enhance weight loss outcomes while minimizing side effects, thereby improving patient adherence and long-term success in managing weight.

Leveraging its established presence in the aesthetics industry, AbbVie believes it is well-positioned to integrate weight loss solutions. The company anticipates the weight-loss drug market will generate approximately $150 billion annually within the next decade, signaling a major opportunity.